M
Mircea Dediu
Researcher at National Institutes of Health
Publications - 44
Citations - 8201
Mircea Dediu is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Carboplatin. The author has an hindex of 18, co-authored 41 publications receiving 7817 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,E. Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: There was a significant reduction in the risk of disease progression over the placebo group, and the primary endpoint was progression-free survival in the intention-to-treat population.
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.
Journal ArticleDOI
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Nick Thatcher,Fred R. Hirsch,Alexander Luft,Aleksandra Szczesna,Tudor Ciuleanu,Mircea Dediu,Rodryg Ramlau,Rinat Galiulin,Beatrix Bálint,György Losonczy,Andrzej Kazarnowicz,Keunchil Park,C. Schumann,Martin Reck,H. Depenbrock,Shivani Nanda,Anamarija Kruljac-Letunic,Raffael Kurek,Luis Paz-Ares,Mark A. Socinski +19 more
TL;DR: Overall survival was significantly longer in the necitumumab plus gemcitabine and cisplatin group than in the gemcitABine and cascplatin alone group and stratified hazard ratio 0·84 [95% CI 0·74-0·96; p=0·01].
Journal ArticleDOI
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss,Andrew Arnold,Frances A. Shepherd,Mircea Dediu,Tudor-Eliade Ciuleanu,David Fenton,Mauro Zukin,David Walde,Francis Laberge,Mark D. Vincent,Peter M. Ellis,Scott A. Laurie,Keyue Ding,Eliot Frymire,I. Gauthier,Natasha B. Leighl,Cheryl Ho,Jonathan Noble,Christopher W. Lee,Lesley Seymour +19 more
TL;DR: The addition of cediranib to carboplatin/paclitaxel results in improved response and PFS, but does not appear tolerable at a 30-mg dose.